# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MDCO-2010 in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery

> **NCT01535222** · PHASE2 · COMPLETED · sponsor: **The Medicines Company** · enrollment: 32 (actual)

## Conditions studied

- Coronary Artery Bypass Graft
- Cardiopulmonary Bypass

## Interventions

- **DRUG:** MDCO-2010
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01535222
- **Lead sponsor:** The Medicines Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2011-05
- **Final completion:** 2011-06
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2012-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01535222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01535222, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MDCO-2010 in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01535222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*